| scholarly article | Q13442814 |
| P50 | author | Jean Davoust | Q56531124 |
| Serge Lebecque | Q57421736 | ||
| Jacques Banchereau | Q55097670 | ||
| P2093 | author name string | J Valladeau | |
| D Bell | |||
| G Netto | |||
| P Chomarat | |||
| K A Palucka | |||
| D Broyles | |||
| G M Harb | |||
| P2860 | cites work | Dendritic cells capable of stimulating T cells in germinal centres | Q60085015 |
| Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts | Q71148644 | ||
| Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells | Q71607047 | ||
| Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability | Q71615065 | ||
| CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha | Q73672017 | ||
| Identification and isolation of CD1a positive putative tumour infiltrating dendritic cells in human breast cancer | Q73672357 | ||
| Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma | Q73850975 | ||
| Reciprocal control of T helper cell and dendritic cell differentiation | Q74452751 | ||
| Dendritic cells as the terminal stage of monocyte differentiation | Q74515427 | ||
| Cancer vaccines | Q74539555 | ||
| Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation | Q77353738 | ||
| Tumor immunology: the glass is half full | Q77769105 | ||
| Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection | Q24561706 | ||
| Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain | Q24602799 | ||
| Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3alpha from lung dendritic cells | Q24652902 | ||
| CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells | Q24652932 | ||
| Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products | Q24678867 | ||
| Dendritic cells and the control of immunity | Q27860918 | ||
| Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha | Q28251443 | ||
| CD1a and S100 antigen expression in skin Langerhans cells in patients with breast cancer | Q28268261 | ||
| A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment | Q28285117 | ||
| Dendritic cells. | Q33653670 | ||
| CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha | Q36367113 | ||
| Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures | Q36376739 | ||
| Immunohistochemical localization of CD1a-positive putative dendritic cells in human breast tumours | Q36618859 | ||
| Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 | ||
| Developmental regulation of MHC class II transport in mouse dendritic cells. | Q41093187 | ||
| An in vitro model of lymphocyte homing. II. Membrane and cytoplasmic events involved in lymphocyte adherence to specialized high-endothelial venules of lymph nodes | Q41331109 | ||
| HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. | Q41438696 | ||
| Dendritic cells: unique leukocyte populations which control the primary immune response | Q41621775 | ||
| Escape from host-antitumor immunity. | Q41756544 | ||
| CD4 T cells and their role in antitumor immune responses | Q41812728 | ||
| Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites | Q42971765 | ||
| Decreased antigen presentation by dendritic cells in patients with breast cancer. | Q44562482 | ||
| Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. | Q47757468 | ||
| Tumor-specific killer cells in paraneoplastic cerebellar degeneration | Q48353734 | ||
| Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. | Q51093180 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dendritic cell | Q506253 |
| breast carcinoma | Q18555947 | ||
| P304 | page(s) | 1417-1426 | |
| P577 | publication date | 1999-11-01 | |
| P1433 | published in | Journal of Experimental Medicine | Q3186912 |
| P1476 | title | In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas | |
| P478 | volume | 190 |
| Q28393278 | A multi-targeted approach to suppress tumor-promoting inflammation |
| Q34768502 | A population of HLA-DR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer |
| Q33622752 | Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine |
| Q47276196 | Activation of tumor-infiltrating antigen presenting cells by high intensity focused ultrasound ablation of human breast cancer |
| Q58861966 | Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific |
| Q42805226 | Alterations of costimulatory molecules and instructive cytokines expressed by dendritic cells in the microenvironment of an endogenous mouse lymphoma |
| Q36671247 | Altered maturation of peripheral blood dendritic cells in patients with breast cancer. |
| Q24806282 | Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer |
| Q36369028 | Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells |
| Q36040825 | Antisense therapy for restenosis following percutaneous coronary intervention. |
| Q36922033 | Apoptotic tumor cells induce IL-27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicity |
| Q87415924 | Association of CD1a-positive dendritic cells with papillary thyroid carcinoma in thyroid fine-needle aspirations: a cytologic and immunocytochemical evaluation |
| Q33713956 | Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity |
| Q34959906 | Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients |
| Q34639884 | Breast cancer and the immune system: opportunities and pitfalls |
| Q36229313 | Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development |
| Q45223770 | CCL20 induces migration and proliferation on breast epithelial cells |
| Q48271829 | CCL20 promotes migration and invasiveness of human cancerous breast epithelial cells in primary culture. |
| Q36373571 | CD1A-positive cells and HSP60 (HSPD1) levels in keratoacanthoma and squamous cell carcinoma |
| Q36671336 | CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer |
| Q42202119 | CD207+/langerin positive dendritic cells in invasive and in situ cutaneous malignant melanoma |
| Q28593562 | CD208/dendritic cell-lysosomal associated membrane protein is a marker of normal and transformed type II pneumocytes |
| Q36915014 | CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer |
| Q73867902 | CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression |
| Q82504535 | CD83(+) dendritic cells and Foxp3(+) regulatory T cells in primary lesions and regional lymph nodes are inversely correlated with prognosis of gastric cancer |
| Q34139732 | Cancer and inflammation: promise for biologic therapy. |
| Q27349546 | Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation |
| Q92970937 | Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment |
| Q34560654 | Cell-based therapy approaches using dying cells: from tumour immunotherapy to transplantation tolerance induction |
| Q33844782 | Changes in immunocompetent cells after interstitial laser thermotherapy of breast cancer |
| Q27012852 | Characteristics of tertiary lymphoid structures in primary cancers |
| Q33726199 | Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma |
| Q60931267 | Chemokines and Chemokine Receptors: Orchestrating Tumor Metastasization |
| Q34002668 | Chemokines and dendritic cell traffic. |
| Q93001507 | Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers |
| Q34119204 | Chemokines in cancer |
| Q83169012 | Chemokines in health and disease |
| Q39337489 | Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy |
| Q33927673 | Chronic histiocytic intervillositis: a placental lesion associated with recurrent reproductive loss |
| Q38150174 | Clinical evaluation of systemic and local immune responses in cancer: time for integration |
| Q36490771 | Combinatorial cancer immunotherapy |
| Q91661897 | Comparative transcriptome analysis of sinonasal inverted papilloma and associated squamous cell carcinoma: Out-HOXing developmental genes |
| Q56966277 | Cytokine production and T-cell activation by macrophage-dendritic cells generated for therapeutic use |
| Q26774345 | Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy |
| Q34129744 | Dendritic cell biology and regulation of dendritic cell trafficking by chemokines |
| Q36644140 | Dendritic cell density and activation status in human breast cancer -- CD1a, CMRF-44, CMRF-56 and CD-83 expression |
| Q36262281 | Dendritic cell dysfunction in cancer: a mechanism for immunosuppression |
| Q36480998 | Dendritic cell immunotherapy for breast cancer |
| Q28584942 | Dendritic cell maturation and chemotaxis is regulated by TRPM2-mediated lysosomal Ca2+ release |
| Q37758502 | Dendritic cell subsets as vectors and targets for improved cancer therapy |
| Q34582889 | Dendritic cell subsets in health and disease. |
| Q34293614 | Dendritic cell vaccination for cancer therapy |
| Q37448957 | Dendritic cell-based therapeutic cancer vaccines: what we have and what we need |
| Q35849249 | Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma. |
| Q53949226 | Dendritic cells and apoptosis in mycosis fungoides. |
| Q37821074 | Dendritic cells and immunity against cancer. |
| Q34216506 | Dendritic cells and immunotherapy for malignant disease |
| Q36569018 | Dendritic cells and tumor microenvironment: a dangerous liaison |
| Q34295082 | Dendritic cells as a tool to induce anergic and regulatory T cells |
| Q41520681 | Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? |
| Q37513871 | Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4 |
| Q37945301 | Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons? |
| Q38180723 | Dendritic cells, T-cells and epithelial cells: a crucial interplay in immunopathology of primary Sjögren's syndrome. |
| Q37176078 | Dendritic cells: at the clinical crossroads |
| Q34983449 | Dendritic cells: making progress with tumour regression? |
| Q36284556 | Dendritic cells: tools and targets for antitumor vaccination |
| Q47597822 | Different morphology, stage and treatment affect immune cell infiltration and long-term outcome in patients with non-small-cell lung carcinoma |
| Q37755322 | Disarming dendritic cells: a tumor strategy to escape from immune control? |
| Q36238138 | Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response. |
| Q47757366 | Distribution of tumor-infiltrating dendritic cells in human non-small cell lung carcinoma in relation to apoptosis |
| Q35051585 | Duodenal follicular lymphoma: comprehensive gene expression analysis with insights into pathogenesis |
| Q50850999 | Ectopic lymphoid structures in primary cutaneous melanoma. |
| Q33939602 | Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1alpha chemokine genes |
| Q36082990 | Enhancement of clonogenicity of human multiple myeloma by dendritic cells |
| Q33193291 | Estrogen receptor alpha is a novel marker expressed by follicular dendritic cells in lymph nodes and tumor-associated lymphoid infiltrates |
| Q35238598 | Exodus-1 (CCL20): evidence for the participation of this chemokine in spontaneous labor at term, preterm labor, and intrauterine infection. |
| Q26779184 | Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy |
| Q28216686 | Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function |
| Q34363958 | Fluorescent-tilmanocept for tumor margin analysis in the mouse model |
| Q36620776 | Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity |
| Q78576588 | Gangliosides inhibit the development from monocytes to dendritic cells |
| Q40063917 | Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells |
| Q47211573 | Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration |
| Q37700841 | Harnessing human dendritic cell subsets for medicine |
| Q37809463 | Harnessing the Effect of Adoptively Transferred Tumor‐Reactive T Cells on Endogenous (Host‐Derived) Antitumor Immunity |
| Q37290803 | Heparanase expression, degradation of basement membrane and low degree of infiltration by immunocytes correlate with invasion and progression of human gastric cancer |
| Q39766695 | High-throughput profiling of tissue and tissue model microarrays: Combined transmitted light and 3-color fluorescence digital pathology. |
| Q92341987 | Host tissue determinants of tumour immunity |
| Q37797963 | How do Tumors Actively Escape from Host Immunosurveillance? |
| Q40223687 | Human CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-β. |
| Q92316756 | Human Tumor-Infiltrating Dendritic Cells: From in Situ Visualization to High-Dimensional Analyses |
| Q37121744 | Human breast cancer-derived soluble factors facilitate CCL19-induced chemotaxis of human dendritic cells. |
| Q74297403 | Identification of a new subset of cells exhibiting dendritic phenotypes in patients affected by breast proliferative disorders |
| Q36670001 | Immunobiology of the sentinel lymph node and its potential role for antitumour immunity |
| Q35967042 | Immunological aspects of head and neck cancer: biology, pathophysiology and therapeutic mechanisms. |
| Q34187201 | Immunomodulatory effects of cyclophosphamide and implementations for vaccine design |
| Q37233774 | Immunosuppressive networks in the tumour environment and their effect in dendritic cells |
| Q29619244 | Immunosuppressive networks in the tumour environment and their therapeutic relevance |
| Q57765037 | In Melanoma Changes of Immature and Mature Dendritic Cell Expression Correlate with Tumor Thickness: An Immunohistochemical Study |
| Q61767300 | Increased serum transforming growth factor-beta1 in human colorectal cancer correlates with reduced circulating dendritic cells and increased colonic Langerhans cell infiltration |
| Q39004228 | Induction of dendritic cell maturation in the skin microenvironment by soluble factors derived from colon carcinoma |
| Q36441408 | Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. |
| Q33425860 | Interaction between CXCR4 and CCL20 pathways regulates tumor growth |
| Q36975749 | Interactions of tumor cells with dendritic cells: balancing immunity and tolerance |
| Q47606249 | Interplay Between Microenvironmental Abnormalities and Infectious Agents in Tumorigenesis |
| Q36568998 | Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention |
| Q37586916 | Long-term pegylated interferon-alpha and its potential in the treatment of melanoma |
| Q39096364 | Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer |
| Q36368813 | Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. |
| Q45886594 | Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity |
| Q37248929 | Many Roles of CCL20: Emphasis on Breast Cancer |
| Q37084499 | Mature dendritic cells infiltrate the T cell-rich region of oral mucosa in chronic periodontitis: in situ, in vivo, and in vitro studies |
| Q37712385 | Mechanism of immune evasion in breast cancer |
| Q42317065 | Melanomas and Dysplastic Nevi Differ in Epidermal CD1c+ Dendritic Cell Count |
| Q24792515 | Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2 |
| Q34250645 | Migration of dendritic cells into lymphatics-the Langerhans cell example: routes, regulation, and relevance. |
| Q40829140 | Modulation of dendritic cell phenotype and mobility by tumor cells in vitro |
| Q38994510 | Molecular and Cellular Mechanisms of Antitumor Immune Response Activation by Dendritic Cells |
| Q38918609 | Molecular mechanisms involved in dendritic cell dysfunction in cancer |
| Q36568993 | More than structural cells, fibroblasts create and orchestrate the tumor microenvironment |
| Q34087806 | Mutations in BALB mitochondrial DNA induce CCL20 up-regulation promoting tumorigenic phenotypes |
| Q26801832 | Myeloid Cells as Targets for Therapy in Solid Tumors |
| Q37866598 | Natural killer cells and solid tumors. |
| Q35095352 | Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored |
| Q58997331 | Nonneuronal Cholinergic System in Breast Tumors and Dendritic Cells: Does It Improve or Worsen the Response to Tumor? |
| Q36611476 | Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer |
| Q54378300 | Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil". |
| Q45893667 | Overexpression of B7-H4 in tumor infiltrated dendritic cells |
| Q64071715 | Oxymatrine‑mediated maturation of dendritic cells leads to activation of FOXP3+/CD4+ Treg cells and reversal of cisplatin‑resistance in lung cancer cells |
| Q53435660 | Paracrine CCL20 loop induces epithelial-mesenchymal transition in breast epithelial cells. |
| Q26777205 | Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate |
| Q44378754 | Peritoneal dialysis solutions inhibit the differentiation and maturation of human monocyte-derived dendritic cells: effect of lactate and glucose-degradation products |
| Q99581556 | Peritumoral immune infiltrates in primary tumours are not associated with the presence of axillary lymph node metastasis in breast cancer: a retrospective cohort study |
| Q35953140 | Plasmacytoid dendritic cells in immunity |
| Q37735454 | Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors |
| Q37436931 | Polymorphism in Exon 2 of CD1 Genes in Southwest of Iran |
| Q51050849 | Primary Human Blood Dendritic Cells for Cancer Immunotherapy-Tailoring the Immune Response by Dendritic Cell Maturation. |
| Q55440274 | Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis. |
| Q33915672 | Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer |
| Q40467105 | Recombinant cholera toxin B subunit activates dendritic cells and enhances antitumor immunity. |
| Q33581986 | Reprogramming tumor-infiltrating dendritic cells for CD103+ CD8+ mucosal T-cell differentiation and breast cancer rejection |
| Q40632606 | Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells. |
| Q41132577 | Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12. |
| Q36376567 | Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody |
| Q47172248 | Role of CCL20/CCR6 and the ERK signaling pathway in lung adenocarcinoma |
| Q55497094 | Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player? |
| Q92441659 | Role of Dendritic Cells in Exposing Latent HIV-1 for the Kill |
| Q35784552 | Role of infiltrated leucocytes in tumour growth and spread |
| Q74583516 | S-100 protein+ dendritic cells and CD34+ dendritic interstitial cells in thyroid lesions |
| Q26752817 | Sensitivity of Dendritic Cells to Microenvironment Signals |
| Q38067641 | Shaping of NK cell responses by the tumor microenvironment |
| Q39865711 | Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg |
| Q37366273 | Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients |
| Q34480685 | Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. |
| Q34103579 | Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells |
| Q38825933 | T Lymphocyte Inhibition by Tumor-Infiltrating Dendritic Cells Involves Ectonucleotidase CD39 but Not Arginase-1. |
| Q34088604 | T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts |
| Q35623903 | T(H)17 cells in tumour immunity and immunotherapy. |
| Q38970585 | Targeting the Bone Marrow Microenvironment. |
| Q38289041 | Targeting the bone marrow microenvironment in multiple myeloma. |
| Q36936355 | Targeting tumour-associated macrophages |
| Q47194123 | Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease? |
| Q35170144 | Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients |
| Q30333360 | The CC chemokine CCL20 and its receptor CCR6. |
| Q37287170 | The Janus face of dendritic cells in cancer |
| Q42017071 | The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues |
| Q35338729 | The emerging understanding of myeloid cells as partners and targets in tumor rejection |
| Q40369714 | The ratio between dendritic cells and T cells determines the outcome of their encounter: proliferation versus deletion |
| Q33993124 | The role of chemoattractant receptors in shaping the tumor microenvironment. |
| Q37922793 | Therapeutic targeting of B7-H1 in breast cancer. |
| Q34681491 | Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation |
| Q33466556 | Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer |
| Q89509415 | Toll-like Receptors from the Perspective of Cancer Treatment |
| Q36736462 | Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer |
| Q37598949 | Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses |
| Q30433292 | Tumor masses support naive T cell infiltration, activation, and differentiation into effectors |
| Q37832693 | Tumor microenvironment is multifaceted |
| Q35016950 | Tumor secretion of CCL22 activates intratumoral Treg infiltration and is independent prognostic predictor of breast cancer |
| Q38123166 | Tumor-altered dendritic cell function: implications for anti-tumor immunity |
| Q33763653 | Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. |
| Q37085136 | Tumour immunity: effector response to tumour and role of the microenvironment |
| Q27005794 | Understanding high endothelial venules: Lessons for cancer immunology |
| Q35070183 | Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling |
| Q35835785 | Using signaling pathways to overcome immune tolerance to tumors |
| Q37477262 | microRNA-155 deficiency impairs dendritic cell function in breast cancer |
Search more.